INTRODUCTION
Patients with acute leukemia who are refractory to initial and reinduction chemotherapy have a dismal prognosis unless they undergo hematopoietic cell transplantation (HCT). 1, 2 Studies have been undertaken to assess the outcomes of transplantation for patients with primary refractory (PREF) acute myeloid leukemia (AML), [3] [4] [5] but among patients with acute lymphoblastic leukemia (ALL), considerable skepticism remains regarding whether transplantation can result in longterm survival in patients who are not in complete remission (CR) at the time of transplantation.
Due to a lack of studies specifically examining PREF ALL, to the best of our knowledge there are no known factors potentially influencing transplantation outcomes in these patients. Therefore, decisions regarding whether to proceed into transplantation cannot be evidence based. We believe that identifying these factors and clarifying the outcomes of HCT in patients with PREF ALL is particularly important at the time of introduction of novel therapies for chemotherapyrefractory ALL.
MATERIALS AND METHODS

Study Design and Data Collection
The current study was a retrospective multicenter analysis performed by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). The EBMT promotes all activity aiming to improve stem cell transplantation or cellular therapy, which includes registering all the activity relating to stem cell transplantations. Data are entered, managed, and maintained in a central database with Internet access; each EBMT center is represented in this database. Quality control measures included several independent systems: confirmation of the validity of the entered data by the reporting team, selective comparison of the survey data with Minimum Essential Data A (MED-A) data sets in the EBMT registry database, cross-checking with the national registries, and regular in-house and external data audits. Since 1990, patients have provided informed consent authorizing the use of their personal information for research purposes. Eligibility criteria for the current analysis included adult patients who underwent their first HCT for PREF ALL from 2000 through 2012. PREF disease was defined as a failure to achieve a morphological CR (<5% of blasts in the bone marrow) after 2 courses of induction chemotherapy. Patients aged <18 years and those with lymphoblastic lymphoma were excluded.
The list of institutions reporting data included in the current study is available in the Supporting Information.
Statistical Analysis
Long-term follow-up data were available for all patients. The main endpoints of the current study were survival, defined as the time to death from any cause; CR rate; leukemia-free survival (LFS); and nonrecurrence mortality (NRM). All outcomes were measured from the time of stem cell infusion. LFS was defined as survival in CR. NRM was defined as death without previous disease recurrence/progression. Acute and chronic graft-versus-host disease (GVHD) were graded according to standard criteria. All patients were considered to be assessable for acute GVHD after day 11. The presence of chronic GVHD was evaluated among patients who demonstrated sustained engraftment from day 1100 after transplantation.
The probabilities of overall survival and LFS were calculated using the Kaplan-Meier estimator. 6 The probabilities of CR, NRM, and acute and chronic GVHD were calculated using the cumulative incidence estimator to accommodate for competing risks. 7 For NRM, disease progression was the competing risk, and NRM was the competing risk for disease progression. For acute and chronic GVHD, death without the event was the competing risk. A Cox proportional hazards model was used for multivariate regression. Factors with a P<.10 in univariate analysis were entered into the multivariate analysis. Results were expressed as the hazard ratio (HR) with the 95% confidence interval (95% CI). Proportional hazards assumptions were checked systematically for all proposed models using the Grambsch-Therneau residual-based test. All tests were 2-sided. The type 1 error rate was fixed at 0.05 for the determination of factors associated with timeto-event outcomes. Statistical analyses were performed with SPSS (version 22.0; IBM Corporation, Armonk, NY) and R (version 3.1.2; R Development Core Team, Vienna, Austria) statistical software packages.
RESULTS
Demographic and Transplantation Details
Patient and transplantation characteristics are summarized in Table 1 . Of 86 patients included in the current analysis, 70 individuals underwent transplantation using a myeloablative conditioning regimen, 52 of whom received a total body irradiation (TBI)-based regimen (median dose, 12 grays [Gy]; range, 8-14 Gy); 16 patients underwent transplantation using a reduced-intensity conditioning regimen, as defined by the EBMT criteria. 8 In 6 patients, the reduced-intensity conditioning regimen incorporated TBI at a dose of 6 Gy. In vivo T-cell depletion was used in 28 patients (33%) (antithymocyte globulin was used in all but 6 patients who received alemtuzumab). No patients included in the current study received blinatumomab or inotuzumab at any point during their disease course.
Engraftment, Early Response, and GVHD
A total of 76 patients (89%) demonstrated neutrophil engraftment at a median of 18 days (range, 9-87 days) after transplantation and 9 patients (11%) experienced primary graft failure. A total of 66 patients (79%) patients achieved CR after transplantation at a median of 31 days (range, 28-147 days); 18 patients (21%) failed to achieve CR. GVHD of grade 2 was documented in 28 patients (33%), whereas 14 patients (17%) experienced grade 3/4 acute GVHD. Chronic GVHD of any severity developed in 27 patients (32%) among those surviving >100 days.
Original Article
Long-Term Outcomes
With a median follow-up of 106 months (range, 9-181 months), 20 patients were alive and free of leukemia at the time of last follow-up. The probability of survival (Fig.  1a) for the entire group was 36% (95% CI, 25%-46%) at 2 years and 23% (95% CI, 13%-32%) at 5 years. The probabilities of LFS and NRM at 2 years and 5 years were 28% (95% CI, 18%-38%) and 17% (95% CI, 8%-25%), respectively, and 20% (95% CI, 12%-29%) and 29% (95% CI, 19%-39%), respectively. Causes of death for the entire cohort were original disease in 40 patients (61%), GVHD in 11 patients (17%), infection in 7 patients (11%), and hemorrhage in 2 patients (3%). Six patients died of other rare transplantation-related causes. For patients achieving a CR, the survival rate was 36% (95% CI, 25%-46%) and 29% (95% CI, 18%-41%), respectively, at 2 years and 5 years, and the incidence of disease recurrence was 51% (95% CI, 38%-63%) and 54% (95% CI, 41%-66%), respectively, at 2 years and 5 years.
Donor lymphocytes were used in 14 patients: in 4 patients preemptively and in 10 patients after disease recurrence. One patient who received preemptive lymphocytes was alive at the time of last follow-up, 122 months after the infusion (126 months after the HCT). Two patients who received donor lymphocyte infusions as treatment of disease recurrence were alive at 97 months and 115 months, respectively, after the infusion (118 months and 123 months, respectively, after transplantation). The second patient also underwent a second HCT at 1 month after the donor lymphocyte infusion. A total of 11 patients underwent a second allogeneic HCT for disease recurrence at a median of 8 months (range, 2-57 months) after their original transplantation for PREF ALL. Only 2 patients were alive after a second allograft at the time of last follow-up, 54 months and 96 months, respectively, after the second HCT (61 months and 123 months, respectively, after first HCT).
Prognostic Factors
The results of the univariate analysis are shown in Table 2 .
In multivariate analysis, the use of TBI was associated with improved survival (HR, 0.53; 95% CI, 0.29-0.973 [P 5
.04]) (Fig. 1b) . Conditioning intensity was not found to be associated with the studied outcomes in this population. We developed a score based on the summation of the number of prognostic factors found to be significant for LFS by multivariate analysis: use of TBI and infusion of female hematopoietic cells into male recipients. This allows for the delineation of 3 prognostic groups as follows: score 2 (both prognostic factors present; 14 patients): 5-year survival rate of 57% (95% CI, 31%-83%) and 5-year LFS rate of 50% (95% CI, 24%-76%); score 1 (only 1 prognostic factor present; 45 patients): 5-year survival rate of 22% (95% CI, 9%-34%) and 5-year LFS rate of 12% (95% CI, 2%-22%); and score 0 (no prognostic factors present; 24 patients): 5-year survival rate and LFS rate of 8% (95% CI, 0%-19%) (Fig. 1c) .
DISCUSSION
The results of the current study demonstrated that HCT can induce long-term survival in patients with PREF ALL because 29% of the patients studied herein were alive 5 years after transplantation. The LFS rate was 17% and the NRM rate was 29% at 5 years in this cohort who underwent transplantation between 2000 and 2012. Naturally, the population of patients in the current study represents a selected subgroup who were judged fit enough to proceed to transplantation and had an available donor.
In comparison with the early results of transplantation in patients with PREF ALL, 2 the data from the current study speak for improved NRM with a similar LFS rate: 38 patients who underwent transplantation between 1982 and 1989 had an LFS rate of 23% and an NRM rate of 44% at 3 years. A more recent study included patients with ALL who underwent transplantation between 1995 and 2004 while not in CR due to both recurrent and PREF disease. Their probability of survival at 3 years was 16% for the entire cohort. The survival of the PREF subgroup was not published, but they had significantly better outcomes compared with patients with disease recurrence. 9 Clinicians accepting the usefulness of allogeneic HCT in patients with PREF AML should not be skeptical regarding its use in PREF ALL because the results of the current study compare well with those from studies regarding allografting in patients with AML. 5, 9, 10 Outcomes of HCT within the current study cohort varied according to pretransplantation variables, which allowed for the development of a predictive scoring system. Higher-risk patients had a 5-year survival rate of only 6%, whereas the 5-year survival rate for patients at lower risk was 57%, which is nearly comparable to the outcomes noted among patients who underwent transplantation while in CR. Although this scoring system requires validation, it provides a basis for future studies. Two clinically important factors predicting long-term survival were defined: the use of conditioning regimens containing TBI and the use of female hematopoietic cells in male recipients. It is interesting to note that these are potentially modifiable factors; the use of TBI is possible in many patients and often is the clinician's choice. In addition, for some male patients, it is possible to select a female donor.
There still is uncertainty regarding the optimal conditioning regimen in patients with ALL. Our observations are in keeping with the results of several published trials suggesting the superiority of TBI-containing regimens. [11] [12] [13] Although in the most recent of these studies intravenous busulfan was the most common chemotherapy-only regimen, 11 some doubts remain regarding whether the intravenous administration could eliminate the survival advantages of TBI in patients with ALL as appears to be the case in patients with PREF AML. 10 Improved LFS in male recipients of female hematopoietic cells also has been described previously in several hematological malignancies. It is explained by the presence of female donor T-cells specific for recipient minor histocompatibility antigens encoded by Y chromosome genes. [14] [15] [16] Clinically, this results in an increased graftversus-leukemia effect, which is particularly important in patients who are not in remission at the time of transplantation.
Maintenance therapy rarely is used other than among patients with Philadelphia chromosome-positive ALL after transplantation, 17 mainly because its effects potentially would interfere with the graft-versus-leukemia effects of transplantation. This applies to most currently used antileukemic drugs, except for blinatumomab. 18 Although it is an attractive therapeutic strategy, none of the patients in the current study received blinatumomab. A trial testing its use after allogeneic HCT currently is underway. 19 Because it is registry-based, the current study suffers from some limitations, including missing data such as the administration of tyrosine kinase inhibitors to the 13 patients with Philadelphia chromosome-positive disease. However, because all patients in the current study had refractory ALL and none of the patients underwent transplantation while in CR, it is reasonable to assume that tyrosine kinase inhibitor therapy had no major biological impact on the outcomes of these patients.
The data from the current study support the use of allogeneic HCT in selected patients with PREF ALL who cannot achieve CR. The current study results also demonstrate the need for the introduction of modern therapies capable of improving antileukemic control before transplantation.
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